We leverage the power of the innate and adaptive immune systems with the goal of long-term tumor remissions for patients We leverage the power of the innate and adaptive immune systems with the goal of long-term tumor remissions for patients

Our Approach

Bolt is pioneering a new category of targeted immunotherapies that leverage the precision of antibody targeting with the activation of the innate and adaptive immune systems in the tumor microenvironment.

Patients

BDC-1001 is a HER2 Boltbody™ ISAC that is currently in clinical development for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors.

Our Team

Bolt is a world-class, inclusive community of fearless innovators committed to delivering transformative treatments to cancer patients with unmet medical needs.

Our Approach

Bolt is pioneering a new category of targeted immunotherapies that leverage the precision of antibody targeting with the activation of the innate and adaptive immune systems in the tumor microenvironment.

Patients

BDC-1001 is a HER2 Boltbody™ ISAC that is currently in clinical development for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors.

Our Team

Bolt is a world-class, inclusive community of fearless innovators committed to delivering transformative treatments to cancer patients with unmet medical needs.

Pipeline

Utilizing our Boltbody™ ISAC approach and myeloid biology expertise, we have a built a robust pipeline of immune-stimulating, myeloid-engaging therapeutics.

PlatformTargetIndicationDISCOVERYPRE-CLINICALPHASE I/II
Boltbody ISAC HER2
  • HER2+ Breast Cancer
  • HER2 Low Breast Cancer
  • HER2+ Gastric Cancer
  • Other HER2+ Cancers

PHASE I/II

BDC-1001
Boltbody ISAC CEA
  • Non-Small Cell Lung Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Breast Cancer

PRE-CLINICAL

Boltbody ISAC PD-L1
  • Checkpoint Inhibitor Refractory Tumors

PRE-CLINICAL

Myeloid ModulatorTAM1
  • KRAS mutated cancer
  • TP53 mutated cancer

PRE-CLINICAL

Highlights

Press Release

Press Release

Bolt Biotherapeutics Presents BDC-1001 Ongoing Clinical Trial Design and Supportive Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting

Podcast

Podcast

Dr. Randy Schatzman On Dodging Disruption: The New Fundraising Norm

Business of Biotech Podcast

Press Release

Press Release

Bolt Biotherapeutics Closes $93.5 Million Series C Financing

Podcast

Podcast

CMC Considerations For In-Human Studies with Drs. Edith Perez and Nathan Ihle

Business of Biotech Podcast